Connection

Patrick Flume to United States

This is a "connection" page, showing publications Patrick Flume has written about United States.
Connection Strength

0.506
  1. Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 12; 160(6):2042-2050.
    View in: PubMed
    Score: 0.078
  2. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2021 02; 159(2):537-543.
    View in: PubMed
    Score: 0.074
  3. Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 07; 19(4):569-574.
    View in: PubMed
    Score: 0.071
  4. The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans? Ann Intern Med. 2017 04 18; 166(8):599-600.
    View in: PubMed
    Score: 0.058
  5. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):139-40.
    View in: PubMed
    Score: 0.054
  6. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8.
    View in: PubMed
    Score: 0.050
  7. Smoothing the transition from pediatric to adult care: lessons learned. Curr Opin Pulm Med. 2009 Nov; 15(6):611-4.
    View in: PubMed
    Score: 0.035
  8. Emergency preparedness for the chronically ill. Am J Nurs. 2005 Mar; 105(3):68-72.
    View in: PubMed
    Score: 0.025
  9. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
    View in: PubMed
    Score: 0.017
  10. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
    View in: PubMed
    Score: 0.015
  11. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
    View in: PubMed
    Score: 0.015
  12. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.